Henlius Ships First Batch of Serplulimab to India, Expanding Global Access to Innovative Cancer Treatment

Reuters

2025/08/01

Henlius Ships First Batch of Serplulimab to India, Expanding Global Access to Innovative <a href="https://laohu8.com/S/CTHZ">Cancer Treatment</a>

Henlius, a subsidiary of Fosun International Limited, has successfully completed its first shipment of serplulimab to India. This anti-PD-1 monoclonal antibody, marketed under the trade name Hetronifly® in Europe, is now the first and only commercialized therapy in India for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). The product has been approved in nearly 40 countries and regions, covering close to half of the global population. This entry into the Indian market exemplifies Henlius' commitment to expanding global patient access to high-quality, innovative medicines. Since its launch, serplulimab has benefited over 110,000 patients globally. Henlius plans to continue leveraging its global capabilities in research, development, manufacturing, and commercialization to provide innovative treatments to patients worldwide.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fosun International Limited published the original content used to generate this news brief on August 01, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2556481177"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2556481177\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2556481177?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-01 22:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2556481177","market":"fut","top_or_hot":-1,"title":"Henlius Ships First Batch of Serplulimab to India, Expanding Global Access to Innovative Cancer Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Henlius Ships First Batch of Serplulimab to India, Expanding Global Access to Innovative <a href=\"https://laohu8.com/S/CTHZ\">Cancer Treatment</a>\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Henlius, a subsidiary of Fosun International Limited, has successfully completed its first shipment of serplulimab to India. This anti-PD-1 monoclonal antibody, marketed under the trade name Hetronifly® in Europe, is now the first and only commercialized therapy in India for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). The product has been approved in nearly 40 countries and regions, covering close to half of the global population. This entry into the Indian market exemplifies Henlius' commitment to expanding global patient access to high-quality, innovative medicines. Since its launch, serplulimab has benefited over 110,000 patients globally. Henlius plans to continue leveraging its global capabilities in research, development, manufacturing, and commercialization to provide innovative treatments to patients worldwide.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fosun International Limited published the original content used to generate this news brief on August 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Henlius Ships First Batch of Serplulimab to India, Expanding Global Access to Innovative Cancer Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHenlius Ships First Batch of Serplulimab to India, Expanding Global Access to Innovative Cancer Treatment\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-08-01 22:04</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Henlius Ships First Batch of Serplulimab to India, Expanding Global Access to Innovative <a href=\"https://laohu8.com/S/CTHZ\">Cancer Treatment</a>\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Henlius, a subsidiary of Fosun International Limited, has successfully completed its first shipment of serplulimab to India. This anti-PD-1 monoclonal antibody, marketed under the trade name Hetronifly® in Europe, is now the first and only commercialized therapy in India for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). The product has been approved in nearly 40 countries and regions, covering close to half of the global population. This entry into the Indian market exemplifies Henlius' commitment to expanding global patient access to high-quality, innovative medicines. Since its launch, serplulimab has benefited over 110,000 patients globally. Henlius plans to continue leveraging its global capabilities in research, development, manufacturing, and commercialization to provide innovative treatments to patients worldwide.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fosun International Limited published the original content used to generate this news brief on August 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1230","symbol_name":"工業集團企業","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250801:nNDL2WwKkK:1","article_id":"2556481177","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2556481177","pubTimestamp":1754057060,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Henlius, a subsidiary of Fosun International Limited, has successfully completed its first shipment of serplulimab to India. This anti-PD-1 monoclonal antibody, marketed under the trade name Hetronifly in Europe, is now the first and only commercialized therapy in India for the first-line treatment of extensive-stage small cell lung cancer . The product has been approved in nearly 40 countries and regions, covering close to half of the global population. This entry into the Indian market exemplifies Henlius' commitment to expanding global patient access to high-quality, innovative medicines. Since its launch, serplulimab has benefited over 110,000 patients globally. Henlius plans to continue leveraging its global capabilities in research, development, manufacturing, and commercialization to provide innovative treatments to patients worldwide.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate a","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1230":"工业集团企业","BK1161":"生物科技","00656":"复星国际","02696":"复宏汉霖"},"translate_title":"复宏汉霖向印度运送首批Serplulimab，扩大全球创新癌症治疗的可及性","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02696":0.9,"00656":0.9},"content_text":"Henlius Ships First Batch of Serplulimab to India, Expanding Global Access to Innovative Cancer Treatment\n\n\n        Henlius, a subsidiary of Fosun International Limited, has successfully completed its first shipment of serplulimab to India. This anti-PD-1 monoclonal antibody, marketed under the trade name Hetronifly® in Europe, is now the first and only commercialized therapy in India for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). The product has been approved in nearly 40 countries and regions, covering close to half of the global population. This entry into the Indian market exemplifies Henlius' commitment to expanding global patient access to high-quality, innovative medicines. Since its launch, serplulimab has benefited over 110,000 patients globally. Henlius plans to continue leveraging its global capabilities in research, development, manufacturing, and commercialization to provide innovative treatments to patients worldwide.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fosun International Limited published the original content used to generate this news brief on August 01, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}